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Abstract
Background and Objectives: Damage to intestinal mucosa in celiac disease (CD) is mediated both by inflammation due to
adaptive and innate immune responses, with IL-15 as a major mediator of the innate immune response, and by proliferation
of crypt enterocytes as an early alteration of CD mucosa causing crypts hyperplasia. We have previously shown that gliadin
peptide P31-43 induces proliferation of cell lines and celiac enterocytes by delaying degradation of the active epidermal
growth factor receptor (EGFR) due to delayed maturation of endocytic vesicles. IL-15 is increased in the intestine of patients
affected by CD and has pleiotropic activity that ultimately results in immunoregulatory cross-talk between cells belonging
to the innate and adaptive branches of the immune response. Aims of this study were to investigate the role of P31-43 in
the induction of cellular proliferation and innate immune activation.
Methods/Principal Findings: Cell proliferation was evaluated by bromodeoxyuridine (BrdU) incorporation both in CaCo-2
cells and in biopsies from active CD cases and controls. We used real-time PCR to evaluate IL-15 mRNA levels and FACS as
well as ELISA and Western Blot (WB) analysis to measure protein levels and distribution in CaCo-2 cells. Gliadin and P31-43
induce a proliferation of both CaCo-2 cells and CD crypt enterocytes that is dependent on both EGFR and IL-15 activity. In
CaCo-2 cells, P31-43 increased IL-15 levels on the cell surface by altering intracellular trafficking. The increased IL-15 protein
was bound to IL15 receptor (IL-15R) alpha, did not require new protein synthesis and functioned as a growth factor.
Conclusion: In this study, we have shown that P31-43 induces both increase of the trans-presented IL-15/IL5R alpha
complex on cell surfaces by altering the trafficking of the vesicular compartments as well as proliferation of crypt
enterocytes with consequent remodelling of CD mucosa due to a cooperation of IL-15 and EGFR.
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Introduction
Celiac disease (CD) is characterised by derangement of both the
adaptive and the innate immune responses to gliadin, that is a
storage protein of wheat. Some gliadin peptides that are
deamidated by tissue transglutaminase (e.g., A-gliadin P57-68)
bind to HLA DQ2 and/or DQ8 molecules and induce an adaptive
Th1 pro-inflammatory response [1]. There is also evidence that
gliadin contains other peptides (i.e., P31-43) able to initiate a
response involving innate immunity [2,3].
Damage to the intestinal mucosa in CD is mediated both by
inflammation due to the adaptive and innate immune responses
(with IL-15 as a major mediator of the innate immune response)
and by proliferation of crypt enterocytes as an early alteration of
CD mucosa causing crypt hyperplasia [4–6]. The celiac intestine is
characterised, in fact, by an inversion of the differentiation/
proliferation program of the tissue with a reduction in the
differentiated compartment, up to complete villi atrophy, and an
increase of the proliferative compartment, with crypt hyperplasia
[7,8].
We previously investigated the early events of celiac disease and
in particular the interaction between gliadin peptides and
intestinal epithelial cells. We found that the so-called gliadin toxic
peptide (P31-43) delays endocytic vesicle maturation and conse-
quently reduces epidermal growth factor receptor (EGFR)
degradation and prolongs EGFR activation, which in turn results
in increased cell proliferation and actin modifications in celiac
crypt enterocytes and in various cells lines [9]. P31-43 enters
CaCo-2 cells and intestinal enterocytes, interacts with early
endocytic vesicles [10,11], reduces their motility and delays their
maturation to late endosomes [10]. Taken together, this
information points toward an effect of certain gliadin peptides,
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factor (EGF) signalling as one of the major pathways in the celiac
intestine.
The pro-inflammatory cytokine IL-15 is a major mediator of
innate immune response in CD. In fact, IL-15 is higher in the
lamina propria and the intestinal epithelium of untreated celiac
patients as compared with treated patients and controls [3,12,13].
It induces differentiation of dendritic cells [14] and is also secreted
by the intestinal epithelium [15]. Moreover, IL-15 affects the
proliferation, localisation and function of intraepithelial lympho-
cytes (IELs) in the intestinal mucosa of CD patients [16–19].
Gliadin peptides 31-43 and 31-49 are not recognized by T cells
and induce an innate immune response in the celiac mucosa [2].
P31-43-induced activation of various markers of the innate
immune response is inhibited by neutralising anti-IL-15 antibodies
[2]. IL-15 mediates P31-43-induced expression of the stress
molecule MIC-A in enterocytes [3] and reproduces most of the
epithelial modifications caused by gliadin in CD patients,
including IEL migration [12–14]. IL-15 also exerts pleiotropic
activity that ultimately results in immunoregulatory cross-talk
between cells of the innate and adaptive branches of the immune
response [20]. Moreover, IL-15 can induce proliferation in
intestinal epithelial cells [21].
IL-15 expression is tightly regulated at both the transcriptional
and post-transcriptional levels [22–24]. Although IL-15 transcripts
are widely expressed, the IL-15 protein is seldom detected in the
supernatants of cells that display mRNA for this interleukin
[22,24]. IL-15 has been found in the Golgi complex and in
transferrin-carrying endocytic vesicles [25,26]. Trafficking of the
IL-15/IL-15R alpha complex in the endocytic pathway plays a
central role in the regulation of IL-15 expression at the post-
transcriptional level. IL-15 is chaperoned through the secretory
Figure 1. P31-43-induced EGFR- and IL-15-dependent proliferation in CaCo-2 cells. (A) Quantification of BrdU incorporation of CaCo-2
cells incubated overnight with medium alone, or treated as indicated. Columns represent the mean and bars represent the standard deviation of five
independent experiments. More than 300 nuclei were counted for each experiment in several optical fields and the number of BrdU-positive cells was
expressed as a proportion of the total nuclei. *=p,0.05 **p,0.01 (Student’s t-test). (B) Immunofluorescence staining of BrdU incorporation of CaCo-
2 cells treated as indicated. Hoechst stains of total nuclei. Single representative optical fields (63x objective).
doi:10.1371/journal.pone.0017039.g001
Proliferation and Innate Immunity Activation in CD
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e17039pathway by complexing with IL-15 R alpha, as this complex forms
in the Golgi and is transported to the membrane where it recycles
and is trans-presented to neighbouring cells [27–31]. Interestingly,
in the intestine, IL-15 is present on the surface of enterocytes,
which suggests that cell-to-cell contact could play a role in IEL
regulation [13].
The aims of this study were to determine if the proliferative
activity of P31-43 on celiac enterocytes and cells is not only
EGFR-dependent but also mediated by IL-15. We also investi-
gated whether P31-43 increases IL-15 in an intestinal epithelial
cell line (CaCo-2 cells) and the molecular and cellular bases of this
phenomenon in relation to the derangement of the vesicular
function induced by P31-43.
Materials and Methods
Cell culture, materials and transfections
CaCo-2 cells were grown for 5–6 days in Dulbecco’s Modified
Eagle’s Medium (DMEM) (GIBCO, San Giuliano Milanese, Italy),
10% fetal calf serum (GIBCO), 100 units/ml penicillin-strepto-
mycin (GIBCO), and 1 mM glutamine (GIBCO) with medium
changed every two days.
Synthetic peptides were obtained from Inbios srl (Naples, Italy)
and they were .95% pure as evaluated by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry. Lipopoly-
saccharide (LPS)-free peptides were obtained by Ultrasart-D20
filtration (Sartorius AG, Gottingen, Germany)[9].
The levels of LPS in these peptides were below the detection
threshold, i.e., ,0.20 EU/mg as assessed with the QCL-1000 kit
(Cambrex Corporation, NJ). The P31-43 sequence was LGQ-
QQPFPPQQPY and the P57-68 sequence was QLQPFP-
QPQLPY. Dose/response experiments indicated that the best
concentration of peptides for experiments involving bromodeoxy-
uridine (BrdU) incorporation and IL-15 expression on the cell
surface (Fig. S1) was 100 mg/ml [9].
IL-15 PE-conjugated monoclonal antibody (clone: 34559;
isotype: IgG1) was purchased from R&D Systems (Minneapolis,
MN, USA). Rat isotype-matched PE-labelled control IgG1s were
purchased from Pharmingen (San Diego, CA, USA). Recombinant
humanIL-15(R&DSystems,Minneapolis,MN,USA)wasusedata
concentration of 10 ng/ml for FACS analysis and the blocking
monoclonal anti-human IL-15 antibody (R&D Systems, Minneap-
olis, MN, USA) at 5 mg/ml in all experiments. We used the goat,
anti-humanIL-15R alpha (R&D Systems,Minneapolis, MN,USA),
rabbit anti-human IL-15 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and mouse anti-alpha tubulin (Sigma-Aldrich, Milan,
Italy) and rabbit anti-EGFR (Cell Signaling Celbio, Milan, Italy)
antibodies for western blotting. BrdU was detected with a
Figure 2. P31-43-induced proliferation of crypt enterocytes in celiac disease (CD) biopsies in the active phase of the disease
depends on EGFR and IL-15 functions. (A) Quantification of BrdU incorporation of crypt enterocytes of intestinal biopsies from CD patients
incubated with P31-43, with and without blocking antibodies anti-IL-15 and anti-EGFR. More than 300 cytokeratin-positive cells were counted in
several fields in each sample and the number of BrdU-positive cells was expressed as a proportion of the total cytokeratin-positive cells. Mean and
standard deviation of five independent experiments (Student’s t test). **=p,0.01; ***=p,0.001 (B) Quantification of BrdU incorporation of crypt
enterocytes of intestinal biopsies from controls incubated with P31-43. More than 300 cytokeratin-positive cells were counted in several fields in each
sample and the number of BrdU-positive cells was expressed as a proportion of the total cytokeratin-positive cells. Mean and standard deviation of
three independent experiments (C) Immunofluorescence of crypts of duodenal biopsies from patients with active CD stained for cytokeratin to
identify epithelial cells [red] and for BrdU [green]. Representative single optical field (40x objective). Lumen of the crypt is highlighted by white
arrows. For methods, see supplementary material.
doi:10.1371/journal.pone.0017039.g002
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an anti-mouse-Alexa-488 conjugated secondary antibody (Molec-
ular probes, San Giuliano Milanese, Italy). Nuclei were stained with
Hoechst (Sigma-Aldrich, Milan, Italy). BrdU incorporation exper-
iments to evaluate cell proliferation were carried out as described
elsewhere.
9 Blocking antibodies EGFR (528) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and IL-15 (R&D Systems,
Minneapolis, MN, USA) were used at concentrations of 2 mg/ml
and 5 mg/ml, respectively, for the BrdU assay.
Transfection of siIL-15R alpha was carried out following the
manufacturer’s instructions (QIAGEN) with HIPerFect Transfec-
tion Reagent. Briefly, CaCo-2 cells were incubated in standard
growth conditions and 500 ng of IL-15R alpha siRNA were
diluted in 100 ml of culture medium without serum to give a final
siRNA concentration of 10 nM. Twenty microliters of HIPerFect
Transfection reagent were added to the siRNA mix by vortexing.
The transfection mix was added drop-wise onto the cells which
were incubated for 72 h. Cells were than processed for WB or
FACS analysis. Transfection of IL-15-EGFP was carried out as
described before [25].
Over night (O/N) treatment is intended as 16 h treatment.
IL-15 analysis
CaCo-2 cells were stimulated at 37uC with P31-43, P57-68,
cycloheximide (Sigma-Aldrich, Milan, Italy) or with medium
alone. After incubation, cells were removed from the dish by
scraping on ice and plated in 96-well V-bottom plates (Costar
Celbio, Milan, Italy). Cells were plated at a density of
1610
5 c e l l s / w e l la n dw e r ew a s h e dw i t hP B Sa n da n a l y s e df o r
surface or intracellular cytokine expression. Membrane cyto-
kines were identified by labelling cells with PE-conjugated anti-
IL-15 mAb for 30 min at 4uC. In the experiments to detect
intracellular cytokines, 10 mg/ml brefeldin A (Sigma-Aldrich,
Milan, Italy) was added to the incubation media for 3 h.
Intracellular cytokines were identified as previously reported
[32]. Finally, cells were read with a cytometer. Cycloheximide
was used at a final concentration of 2 mM [33]. Dose-response
curve was done for P31-43 stimulation to find optimal P31-43
concentration (Figure S1).
Some of the cells stimulated with P31-43 or medium alone were
treated with acid buffer (2 mM glycine and 150 mM NaCl) for
10 min at 4uC and then labelled with PE-conjugated anti-IL-15
mAb [28]. Flow cytometry was carried out with a FACSCalibur
system (BD Bioscience, San Diego, CA, USA) and the results were
analysed with CellQuestPro software (BD Bioscience, San Diego,
CA, USA).
Immunoprecipitation
Lysates were prepared as described previously and protein
concentration was measured with a Bio-Rad protein assay
kit (Hercules, CA, USA) [9]. Equal amounts of cell lysates
(2 mg protein/mL) were used for immunoprecipitation. IL-15R
Figure 3. Overnight treatment with gliadin peptide P31-43, but not P57-68, increased levels of IL-15 mRNA in CaCo-2 cells.
Quantitative PCR analysis shows an increase of IL-15 mRNA after O/N treatment of CaCo-2 cells with P31-43 but not after 30 min, 3 h and 6 h. This
increase can be prevented by IL-15 blocking antibodies. RQ=relative quantity of IL-15 mRNA. Columns represent means, and bars are standard
deviations of a representative experiment done in triplicate. Four separate experiments show similar results. UN=untreated. For methods, see
supplementary material.
doi:10.1371/journal.pone.0017039.g003
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goat polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Proteins were immunoblotted with specific
antibodies.
Western blot
Briefly, CaCo-2 cells were starved overnight in DMEM
containing 0.1% FBS and then stimulated with P31-43 for various
intervals at 37uC. Cells were washed twice and resuspended in lysis
buffer. Cell lysates were analysed by SDS-PAGE and transferred
to nitrocellulose membranes (Whatman Gmbh, Dassel, Germany).
The membranes were blocked with 5% non-fat dry milk and
probed with anti-IL-15, anti-IL-15R alpha, anti-tubulin and anti-
EGFR. Bands were visualised with the ECL system (GE
Healthcare, Amersham, Buckinghamshire, UK). Band intensity
was evaluated by integrating all the pixels of the band without the
background, calculated as the average of the pixels surrounding
the band [9].
Organ culture studies
Biopsy fragments from the duodenum were obtained from five
untreated patients with active CD and three controls (affected by
gastroesophageal reflux) for organ culture studies. The protocol of
the study was approved by the Ethical Committee of the
University ‘‘Federico II’’, Naples, Italy (ethical approval: C.E. n.
230/05). Informed written consent was obtained from all patients.
The biopsy fragments were cultivated as reported elsewhere (for
details, see Text S1) [9,34].
Statistical analyses
GraphPad Prism (GraphPad Software, San Diego, CA, USA)
was used for statistical analysis and graphic representation.
Statistical analysis of differences was performed with Student’s t-
test. A p value ,0.05 was considered statistically significant.
Results
P31-43-induced proliferation depends on EGFR and IL-15
functions in CaCo-2 cells and in enterocytes of cultured
biopsies from patients with active celiac disease
We previously demonstrated that P31-43 induces proliferation
of fibroblasts (NIH 3T3 cell line) and of crypt enterocytes from
cultured biopsies of CD patients with active disease but not from
controls. This proliferation is mediated in an EGFR-dependent
manner [9].
We have now investigated whether P31-43 induces proliferation
of an intestinal cell line such as CaCo-2 cells and whether this
effect, as well as the P31-43 induced proliferation of celiac crypt
enterocytes, is mediated not only by EGFR activation but also by
IL-15 function. As shown in Fig. 1, not only EGF and IL-15 but
Figure 4. Gliadin peptide P31-43 increased IL-15/IL-15R alpha complex on the cell surface in CaCo-2 cells. (A) P31-43 increased IL-15 on
the cell surface in CaCo-2 cells. FACS analysis of IL-15 on the cell surface after overnight (O/N), or 3 h or 6 h of treatment (B) with P31-43. Columns
represent means and bars are the standard deviations of ten independent experiments for panel A and three independent experiments for panel B;
*=p,0.05 (Student’s t-test), **=p,0.01 (Student’s t-test) (C) Histogram of one representative experiment of CaCo-2 cells treated O/N with P31-43.
Black dotted curve corresponds to negative control (isotype-matched Ab), the green open curve depicts specific IL-15 staining after medium
treatment and pink open curve is specific IL-15 staining after O/N culture with P31-43.
doi:10.1371/journal.pone.0017039.g004
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percentage of cells that incorporate BrdU. Treatment with P31-43
increased proliferation of CaCo-2 cells from 26.40%65.7% in the
untreated sample to 44.33%64.5%. This proliferation is depen-
dent on IL-15 and EGFR functions. In fact, both IL-15 and EGFR
blocking antibodies reduced the percentage of proliferating cells to
28.57%67.8% with IL-15-blocking antibodies and 26.67%64%
with EGFR-blocking antibodies. Similar results were obtained
when CaCo-2 cells were treated with peptic-tryptic digest of
gliadin (PTG, not shown). Peptide P57-78 had no effect on CaCo-
2 cell BrdU incorporation.
We next investigated whether, in biopsies from CD patients in
the active state of the disease, P31-43-induced proliferation of
enterocytes required IL-15 function. As expected, P31-43 induced
a statistically significant increase in BrdU incorporation in crypt
enterocytes from CD patients (Fig. 2A and C) [9]. Prevention of
P31-43-induced proliferation was accomplished not only with the
use of anti-EGFR blocking antibody (Fig. 2A and C), but also with
IL-15-blocking antibody (Fig. 2A and C) [9]. In fact, after
treatment with IL-15 blocking antibody, the percentage of BrdU-
positive cells decreased from 33%63.4% in the P31-43 treated
sample to 16.5%65.6%. Similar results were obtained when
biopsies from active CD patients were treated with PTG (not
shown). In control patients, neither P31-43 (Fig. 2 B) nor PTG (not
shown) induced any proliferation [9].
Altogether, these data indicate that gliadin peptide-induced
proliferation of CaCo-2 cells and of CD enterocytes is mediated by
both IL-15 and EGFR activities.
Effect of gliadin peptide P31-43 on transcriptional
regulation of IL-15
We treated CaCo-2 cells with P31-43 for 30 min, 3 h, 6 h or
O/N to determine whether the peptide affected IL-15 mRNA
levels. Quantitative PCR analysis showed an increase in IL-15
Figure 5. Acid treatment and siIl15 mRNA reduce the increase of IL-15 expression on CaCo-2 cell surfaces induced by P31-43. (A)
FACS analysis of IL-15 on the cell surface after overnight (O/N) treatment with P31-43. Histogram of one representative experiment of CaCo-2 cells
treated O/N with P31-43 and P31-43 plus acid treatment. Black dotted curve corresponds to negative control (isotype-matched Ab), the green open
curve depicts specific mAb staining after medium treatment, pink open curve is specific mAb staining after O/N with P31-43 and the dotted pink
open curve represents specific mAb staining after O/N with P31-43 plus acid treatment. Data are representative of one of five independent
experiments. (B) siRNA IL-15R alpha reduces P31-43 mediated increase of IL-15 on CaCo-2 cell surfaces. FACS analysis of IL-15 on Caco-2 cell surfaces.
Statistical analysis of ten independent experiments for UN (untreated) and P31-43 O/N treated cells and of four experiments for cells treated with
siRNA IL-15R alpha. Columns represent means and bars are standard deviations. *=p,0.05 (Student’s t-test). (C) Histogram of one representative
experiment of CaCo-2 cells treated O/N with P31-43 and P31-43 plus SiRNA IL-15R alpha. The dotted black curve corresponds to the negative control
(isotype-matched Ab), the green open curve depicts specific IL-15 staining after medium treatment, the pink open curve depicts specific IL-15
staining after treatment with P31-43 and the blue open curve represents specific IL-15 staining after O/N treatment with P31-43 in the presence of
siRNA IL-15R alpha.
doi:10.1371/journal.pone.0017039.g005
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P57-68 was not able to increase IL15 mRNA at the same levels
(Fig. 3). Intriguingly, this increase in IL-15 mRNA is IL-15-
dependent as it can be prevented by IL-15 blocking antibodies.
This finding suggested that P31-43 acts on pre-existing IL-15
protein to further increase IL-15 mRNA accumulation in CaCo-2
cells. Indeed, exogenous IL-15 induced an even greater increase of
IL-15 mRNA than did P31-43. (Methods are described in Text S2)
P31-43 increased IL-15 protein expression on the surface
of CaCo-2 cells, it did not do so in the cytoplasm or in the
cell supernatant
To investigate whether P31-43 affects the expression of IL-15
protein, we evaluated (by FACS analysis) the intracellular and
surface pools of IL-15 in CaCo-2 cells before and after exposure to
P31-43. Overnight treatment with P31-43 did not affect the
intracellular pool of IL-15 (Figure S2) and neither did shorter
treatment times (not shown). We next evaluated whether P31-43
affects the extra-cellular release of IL-15 by CaCo-2 cells. After
overnight incubation with P31-43, there was no statistically
significant increase in IL-15 in the supernatant as measured by
ELISA assay (Figure S3). However, the percentage of IL-15-
positive cells on the surface increased from 22.92%622.24% to
53.20%618.26% after overnight treatment (Fig. 4A). This
increase is specific for P31-43 because the control peptide P57-
68 did not affect the percentage of cells expressing IL-15 on the
surface (from 22.92%622.24% to 17.09%611.98%). IL-15 on the
cell surface appeared to increase in expression after only 3 h of
incubation with P31-43. This increase became statistically
significant after 6 h of incubation, when it was comparable to
that observed after overnight treatment (Fig. 4B). These findings
indicate that either P31-43 increases the production of the IL-15
protein or mobilizes, from a pre-existing protein pool, IL-15 on the
surface of the cells. We next analysed whether protein synthesis
blockade induced by cycloheximide treatment was able to interfere
with P31-43-induced increase of IL-15 on cell surfaces. Cyclohex-
imide treatment failed to prevent the P31-43-mediated expression
of IL-15 on the cell surface (57.42%+/210.52% vs. 52.40+/
28.35, in the absence of cycloheximide) (Fig. 4B), suggesting that
protein synthesis is not required for the P31-43 effect and that IL-
15 is mobilized from an existing intracellular pool to the cell
surface.
Cell surface IL-15 is linked to IL-15R alpha
Duitman et al. demonstrated that membrane-associated IL-15 is
directed to the cell surface in complex with IL-15R alpha, which
serves as a chaperone for its ligand [30]. We therefore investigated
whether cell surface IL-15, which is increased by P31-43, is also
attached to the receptor in CaCo-2 cells (Fig. 5–7). PCR analysis
confirmed the presence of IL-15R alpha mRNA in CaCo-2 cells
(not shown).
In addition, acid treatment known to release IL-15 from the
ligand/receptor complex, reduced IL-15 on the surface of P31-43-
treated CaCo-2 cells, suggesting that membrane-bound IL-15 is
Figure 6. Both IL-15 and IL-15R-alpha expression increase in the isolated membrane fraction after stimulation with P31-43 for
30 min and 3 h. A) Western blot analysis of membrane proteins separated from total cell lysates shows an increase in membrane protein fractions
of IL-15 and IL-15R alpha after P31-43 treatment. B and C) densitometric analysis of the Western blot experiment shown in a. EGFR was used to
normalise membrane protein measurements. Increments (i) of IL-15 and IL-15R alpha were calculated as follows: iIL-15= (IL-15 treated [t]/IL-15
untreated [un])/(EGFR Treated [T]/EGFR Untreated [UN]). iIL-15R =(IL-15R [t]/Il-15R [un]/(EGFR [T]/EGFR [UN]). The blots shown are representative of
three similar independent experiments.
doi:10.1371/journal.pone.0017039.g006
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further confirm this hypothesis, we silenced IL-15R alpha by
transfecting a specific siRNA, which reduced IL-15R alpha
protein expression by almost 50% as shown in Figure S4. In
Fig. 5 C,D the P31-43-induced increase of IL-15 on the cell
surface is significantly inhibited (from 55%+/218% to 24%+/
22.8%) in the presence of siIL-15R alpha. As expected, the
increase of IL-15 on the cell membranes is mirrored by an increase
in IL-15R alpha at the same site. In fact, both FACS analysis of
the cells (not shown) and western blot analysis of proteins isolated
from membrane fraction show an increase in IL-15 and IL-15R
alpha after 30 min and after 3 h of treatment with P31-43 (Fig. 6).
Finally, the existence of an IL-15/IL-15R alpha complex was
demonstrated by analysis of proteins immunoprecipitated by anti-
IL-15R alpha antibody from isolated cell membranes [29]. This
analysis showed both immunoprecipitated IL-15 ligand and
receptor by western blotting using specific antibodies (Fig. 7).
Moreover, treatment with P31-43 increased the association of IL-
15 and IL-15R alpha on the cell membrane by more than three-
fold as compared to untreated cells when analysed by densitom-
etry.
P31-43-induced surface IL-15 is biologically active
Most of the biological activity of IL-15 is believed to be
mediated by the membrane-attached form of the protein [27,28].
We therefore evaluated the functional activity of IL-15 on the
CaCo-2 cell surface by co-culturing irradiated CaCo-2 cells,
treated or not with P31-43, with CTLL2, a cell line responsive to
the mitogenic effects of both IL-15 and IL-2 [35]. As shown in
Fig. 8, the proliferation rate of CTLL2 cells, evaluated as
3H-
thymidine incorporation, increased from 24,945 cpm613,792 of
the untreated sample, to 36,431 cpm613,265 after P31-43
treatment of CaCo-2 cells. As expected, P57-68 treatment of
CaCo-2 cells was not able to induce proliferation of CTLL2
(11,952+/26,108). Furthermore, CTLL2 cells did not proliferate
in response to direct treatment with P31-43 alone (not shown). The
increase of
3H-thymidine incorporation was dependent on IL-15
because IL-15 blocking antibody treatment prevented CTLL2
proliferation induced by CaCo-2 cells treated with P31-43
(21,129+/212,648). This finding indicates that IL-15 increased
on the cell surface after P31-43 treatment can function as a growth
factor. (Methods are described in Text S3)
P31-43 alters trafficking of IL-15-containing recycling
vesicles and increases recycling markers on CaCo-2 cell
surfaces
IL-15 has been found in the Golgi complex and in transferrin-
carrying endocytic vesicles [25,26]. We previously demonstrated
that P31-43 alters the vesicular trafficking [9]. Therefore, we
evaluated whether P31-43 affects the recycling pathway by carrying
more IL-15 to the cell surface. IL15-EGFP localises to a recycling
vesicular compartment when it is transfected in CaCo-2 cells [25].
After treatment with P31-43, IL-15EGFP-containing vesicles
accumulated in the cytosol as shown in Fig. 9 A,B. The fluorescence
intensity of the P31-43-treated cells exhibited a statistically
significant increase from 5462.9 to 79.364.7 after P31-43
treatment. To identify the IL-15EGFP-containing vesicular com-
partment, we treated CaCo-2 cells transfected with IL-15-EGFP
with the recycling marker transferrin-Tex-Red for 90 min. [36]. As
shown in Fig. 9A and B, treatment with P31-43 increased the
number of transferring-containing vesicles, indicating that P31-43
can alter the trafficking of the recycling vesicles (fluorescence
intensity/cell increased from 52.2566.8 to 73.365.6 after P31-43
treatment). Treatment with P57-68 had no effect on the number of
transferring-carrying vesicles. Furthermore, IL-15-EGFP co-local-
ised with transferrin-Tex red in the same vesicular compartment
before and after P31-43 treatment. To confirm P31-43 induced
alterations of the recycling vesicular compartment, we investigated
the levels of recycling marker transferrin receptor on the cell surface
by FACS analysis before and after overnight treatment with P31-43
orP57-68.AsshowninFig.10,thepercentage ofcellsdisplayingthe
transferrin receptor on their surfaces significantly increased (from
18%67% to 34.4%613%) after P31-43 treatment while P57-68
treatment had no effect on the cell surface levels of transferrin
receptor (from 18%67% to 13%64.7%). Therefore, P31-43
increased the expression of recycling vesicle markers on the cell
surface, suggesting that the increase of IL-15 on the cell surface may
relate to re-distribution of IL-15 from an intracellular vesicular
compartment to the cell membrane. (Methods are described in
Text S4.)
Figure 7. P31-43 treatment increases, on the cell membrane, IL-
15/IL-15R alpha association. A) Demonstration of an IL-15/IL-15R
alpha complex in an isolated membrane fraction. WB analysis of
membrane proteins immunoprecipitated with IL-15R alpha antibodies.
IL-15 and IL-15R alpha are visualized in the upper and lower gels with
their respective antibodies. UN=untreated. B) Densitometric analysis of
the Western blot experiment shown in (A). Fold increase of upper band
of IL-15 (black arrow) was calculated respective to the IL-15R alpha
band. The increment of IL-15 association (A) was calculated as follows:
aIL-15= (IL-15 [t]/IL-15 [un])/(IL-15R alpha [T]/IL-15R alpha [UN]). The
blot shown is representative of three independent experiments.
doi:10.1371/journal.pone.0017039.g007
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In this paper, we demonstrate that P31-43-induced cell
proliferation both in crypt enterocytes and in CaCo-2 cells is not
only dependent on EGFR but also on IL-15. P31-43 increased
CaCo-2 cell surface expression of IL-15, the major mediator of
innate immunity in CD, by altering the endocytic trafficking of the
IL-15/IL-15R alpha complex. Thus, gliadin effects on prolifera-
tion and innate immunity activation are mediated by cooperation
between growth factors (EGFR) and innate immunity mediators
(IL-15) due to alterations in vesicular trafficking. It is now well
accepted that endocytosis has many effects on signalling; in fact,
signalling pathways and endocytic pathways are regulated in a
reciprocal manner. It is also widely accepted that the ‘‘Endocytic
Matrix’’ is a master organiser of signalling, governing the
resolution of signals in space and time. Consequently, endocytosis
affects several cell functions that range from proliferation to cell
motility [37].
We first investigated the role of IL-15 in P31-43-induced cell
proliferation. In previously published reports P31-43 has been
found to be delayed in early endocytic vesicles both in crypt
enterocytes of CD atrophic mucosa and in cell lines [9–11]. It has
also been found that P31-43 can interfere with the correct
localisation, on the vesicles surface, of the major coordinator of
vesicle dynamics and maturation, namely the Hepatocyte growth
factor Regulated tyrosine kinase Substrate (HRS) [10]. As a
consequence maturation of the early endocytic compartment is
delayed and the activation of EGFR and other receptors is
prolonged, which results in several different biological events
including cell proliferation [9–10].
In fact, the increase of proliferation of celiac crypt enterocytes
induced by P31-43 was EGFR-dependent, as proliferation
increase could be prevented by inhibitors of this pathway [9]. In
this study, we show that IL-15, EGF and P31-43 or PTG can
induce proliferation of an intestinal cell line such as CaCo-2.
Moreover, we show that P31-43-induced proliferation is depen-
dent on IL-15 and EGFR function. In fact, blockage of either the
EGFR or IL-15 signalling pathways prevented P31-43-induced
proliferation. These observations can be reproduced in intestinal
biopsies from CD patients cultured for 24 hours. In this system, we
show that PTG and peptide P31-43-induced crypt enterocyte
proliferation is dependent not only on EGFR activation but also
on IL-15 activity.
The present data and previously published reports [9] point to
cooperation between a cytokine (IL-15) and a growth factor (EGF)
to induce cellular proliferation. A complex between IL-15R alpha
and EGFR is in fact present in CaCo-2 cells and is increased by
P31-43 treatment (unpublished results). Such cooperation in signal
transduction is not new. In fact, IL-15 and EGFR share the
downstream effectors ERK and STAT [38]. IL-15 also interacts
with the tyrosine kinase receptor AXL to prevent apoptosis in
fibroblasts [39].
We next investigated whether gliadin-induced inflammation in
CD is also affected by P31-43 alterations of the endocytic
compartment. EGFR itself has a leading role in the regulation of
the inflammation and can mediate innate immune responses in
airway epithelium in respiratory diseases [40]. On the other hand,
IL-15 is recognised as a major mediator of innate immunity in
CD. In fact, it is not only increased in CD mucosa [3,12,13], but it
is also necessary for the proliferation, localisation and function of
intraepithelial lymphocytes (IELs) in the intestinal mucosa of CD
patients [16–19]. Moreover, increased IL-15 activity mediates, to a
large extent, the immune response induced by P31-43 in CD [2].
Therefore, we chose IL-15 activity as an indicator of the
inflammation triggered by P31-43 and CaCo-2 cells as a model to
study the capacity of P31-43 to increase IL-15 activity in an effort
to understand the molecular mechanisms underlying this phe-
nomenon.
IL-15 expression is tightly regulated at both transcriptional and
post-transcriptional level [22–24].
Real-time PCR analysis showed that IL-15 mRNA increased
in an IL-15-dependent manner only after prolonged incubation
of CaCo-2 cells with P31-43, which suggests that the effects of
gliadin on IL-15 mRNA could be secondary to other earlier
effects. P31-43 increased IL-15 expression on the cell surface but
not in the cytoplasm or at the level of protein secretion. The
protein increase on the cell surface occurred earlier than the
increase of IL-15 mRNA levels and independently from new
protein biosynthesis, indicating that P31-43 first affected IL-15
protein distribution and then mRNA levels. Previous observations
indicated that intracellular IL-15 localises to recycling vesicles
that contain Transferrin Receptor and to the Golgi complex
[20,25]. Therefore, we investigated the effect of P31-43 on the
early/endosomal vesicle recycling pathway. P31-43 treatment
increased the number of vesicles carrying both IL-15-EGFP and
Transferrin-Tex-Red.
Figure 8. The complex IL-15/IL-15R alpha induced by P31-43 on the surface of CaCo-2 cells functions as a growth factor for CTLL2
cells.
3H-thymidine incorporation by CTLL2 cells induced to proliferate by CaCo-2 cells untreated or treated with P31-43 or P31-43 and anti-IL-15 or
P57-68 was measured. CaCo-2 and CTLL2 cells were co-cultivated overnight. Data are expressed as
3H-TdR (CpM 1610
6 cells). Columns represent the
mean, and bars represent the standard deviation of five independent experiments. *p,0.05 (Student’s t-test). For methods, see supplementary
material.
doi:10.1371/journal.pone.0017039.g008
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induced by P31-43 [9–10] and to the delay of the maturation of
this compartment to lysosomes [10,11]. This could explain the
increase of fluorescence for IL15 in absence of increased IL15
protein synthesis. Moreover, FACS analysis showed that P31-43
increases a typical marker of recycling vesicles, such as the
Trasferrin Receptor, on the cell surface. These data are consistent
with the hypothesis that P31-43-induced alteration of the
endocytic pathway may be responsible for the increase of IL-15
expression on the cell surface.
It has recently been demonstrated that IL-15 is transported to
the cell surface as a complex with its receptor, IL-15R alpha,
which functions as a chaperone for the ligand, through the Golgi
apparatus. This complex represents the trans form of IL-15 and
enables the trafficking of this cytokine through the secretory and
recycling pathways [30]. Here, we have shown that both IL-15
and IL-15R alpha increase in isolated membrane fractions of
CaCo-2 cells after stimulation with P31-43. In addition, we
showed, by immunoprecipitation, the presence of an IL-15/IL-
15R alpha complex in the membrane fraction of CaCo-2 cells
increased by P31-43 treatment. Finally, acid treatment and siRNA
anti-IL-15R alpha reduce the amount of IL-15 present on the cell
surface. Taken together, these data demonstrate that cell surface
IL-15 is linked to the receptor.
The IL-15/IL-15R alpha complex present on the surface of
CaCo-2cellsafterP31-43 treatmentisa functional growthfactorfor
IL-15-sensitive CTLL2 cells. The membrane-bound, trans-present-
ed IL-15 performs a number of IL-15 primary functions [27,28]. In
non-immune cells, trans-presented IL-15 protects fibroblasts and
epithelial cells from apoptosis and induces their proliferation [21]. It
is also capable of inducing angiogenesis, of mediating anabolic
effects in muscle cells, and of stimulating the lipolysis of adipocytes
and the survival of neuronal cells [27]. IL-15 inducesthese effects by
activating intracellular pathways directly by cell-to-cell contact [28].
Figure 9. P31-43 alters trafficking of IL-15-containing recycling vesicles and increases recycling markers expressed on CaCo-2 cell
surfaces. (A) IL-15-EGFP and Transferrin-Tex Red accumulate and co-localise after P31-43 treatment in a recycling vesicular compartment. IL-15-EGFP
was transfected into CaCo-2 cells and observed by microscope after treatment with Transferrin-Tex Red and P31-43. White lines show the area of a
single cell. (63x objective and 2x zoom). IL-15-EGFP (green) co-localises with Transferrin-Tex-Red (red) positive vesicles. Merge of the red and green
panels is shown with yellow/orange colour indicating co-localisation. The co-localisation coefficient was calculated as reported under ‘‘Methods’’. The
results are representative of three independent experiments. For methods, see supplementary material. (B) Statistical analysis of fluorescence
intensity/cell. For treated and untreated samples, three independent experiments were done, measuring fluorescence intensity of 10 cells in random
fields in each experiment. **=p,0.01, ***=p,0.001 (Student t-test). For methods, see supplementary material.
doi:10.1371/journal.pone.0017039.g009
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main effects by altering the trafficking of cell vesicular compart-
ments. This leads to overexpression of the trans-presented IL-15/
IL5R alpha complex, an activator of innate immunity, and, due to
cooperation of IL-15 and EGFR, the proliferation of crypt
enterocytes with consequent remodelling of the CD mucosa.
These observations are relevant to our understanding of the
early events occurring in the celiac mucosa exposed to gliadin
because the increase of IL-15 and IL-15R alpha is a major
event in the initial phases of CD [3,12,13,41]. Our observation
that in the celiac intestine IL-15 plays a major role in the
gliadin-induced proliferation of epithelial cells, one of the
hallmarks of CD, reinforces thei m p o r t a n c eo fo u rr e s u l t s
obtained in CaCo-2 cells and CD biopsies, which may increase
understanding of the pathogenesis of CD. Why the celiac
mucosa seems to be particularly sensitive to the effects of some
gliadin peptides, such as peptide P31-43, remains to be
elucidated. Preliminary data suggest that in CD cells, the
endocytic compartment is morphologically and functionally
altered. We hypothesize that in CD mucosa, an alteration of
t h ev e s i c u l a rc o m p a r t m e n tr e n d e r st h et i s s u em o r es e n s i t i v et o
the effects of gliadin.
Supporting Information
Figure S1 Dose-response effect of P31-43 treatment on
IL-15 expression on CaCo-2 cell surfaces FACS analysis
of IL-15 on Caco-2 cells surfaces after O/N treatment
with varying concentrations of P31-43 peptide. UN=un-
treated. Columns indicate percentage of positive cells (mean and
standard deviation of three independent experiments). *p,0.05
(Student’s t-test). Optimised concentration of P31-43 for IL-15
expression on cell surface was 100 mg/ml.
(TIF)
Figure S2 Overnight treatment with gliadin peptide
P31-43 does not increase intracellular IL-15 expression.
FACS analysis of IL-15 in the cytoplasm of CaCo-2 cells. Columns
indicate percentage of positive cells (mean and standard deviation
of four independent experiments).
(TIF)
Figure 10. P31-43 increases expression of recycling marker transferrin receptor on the cell surface. A) FACS analysis of transferrin
receptor, one experiment is shown. B) Statistical analysis of CaCo-2 cells percentage expressing the recycling marker, Transferrin Receptor, on the cell
surface after P31-43 or P57-68 O/N treatment. Columns represent means and bars are the standard deviations of ten independent experiments.
*p,0.05 (Student’s t test). C) Confocal images of transferrin receptor expression on CaCo-2 cell surfaces. White arrows point to cell surface. 63x
objective.
doi:10.1371/journal.pone.0017039.g010
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P31-43 does not increase secreted IL-15. ELISA assay of
IL-15 in medium of cultured CaCo-2 cells. Columns indicate
pg/ml (mean and standard deviation of three independent
experiments).
(TIF)
Figure S4 siRNA IL-15R alpha reduces IL-15R alpha
protein expression. (A) CaCo-2 cells were transfected with
IL-15R alpha siRNA, lysed and immunoblotted for IL-15R
alpha expression. b-Tubulin was used as an internal control.
(B) Densitometric analysis of IL-15R alpha expression
compared to alpha-tubulin expression. The decrease (d) of
IL-15R alpha was calculated as follows: dIL-15R = (IL-15R
[t]/IL-15R [un])/(Tubulin [T]/Tubulin [UT]). Shown is
o n er e p r e s e n t a t i v ee x p e r i m e n to u to ft h r e ei n d e p e n d e n t
experiments.
(TIF)
Text S1 Organ Culture Study.
(RTF)
Text S2 RNA Extraction and Real-Time PCR.
(RTF)
Text S3 CTLL2 Proliferation Assays.
(RTF)
Text S4 Transferrin and Transferrin Receptor Analy-
sis.
(RTF)
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